O

Otsuka Pharmaceutical

Global pharma maker of Abilify

Senior Manager - Global Regulatory Affairs

Full-Time
$150k - $224.3k/yr+ Incentive opportunity
Mid, Senior
Bachelor's, Master's
Remote in USA
RemoteApproximately 20% travel required.
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • Experience working in the pharmaceutical and/or healthcare industry.
  • Knowledge and experience preparing global regulatory submissions, including Investigational New Drugs, Clinical Trial Applications, New Drug Applications or Biologics License Applications, and Marketing Authorisation Applications.
  • A Bachelor's degree with 5 or more years of experience, or a Master's degree with 2 years of experience, in regulatory affairs or related areas such as clinical development, project management, or quality assurance, within the pharmaceutical or healthcare industry.
  • Strong oral and written communication skills.
  • Solid working knowledge of the drug development process, laws, regulations, and guidelines, including the Food and Drug Administration and International Council for Harmonisation requirements.
  • Ability to interpret and apply regulatory intelligence to work output.
  • Ability to lead teams, prioritize work, proactively manage and communicate issues, and scope progress and risks throughout the project lifecycle while keeping key stakeholders informed.
  • Ability to establish close communication and working relationships with cross-functional teams to meet business objectives.
  • Strong organizational skills and the ability to learn and grow.
  • Strong demonstrated experience with Microsoft Office programs, including Word, Excel, PowerPoint, and Outlook, and familiarity with electronic document management systems.
Responsibilities
  • Support the development of global regulatory strategy, planning, and execution of global investigational and marketed prescription drug submissions, and manage lifecycle regulatory activities for assigned projects in alignment with the Global Regulatory Lead.
  • Identify the need for and obtain regulatory intelligence, research precedent approvals and prior health authority decisions, and assess their applicability to support strategic options for assigned products.
  • Translate complex global requirements and assess associated regulatory challenges for the Global Regulatory Lead, global regulatory team, assigned project teams, and internal and external functional business units.
  • Collaborate with members of the global regulatory team to develop global regulatory plans and address global regulatory issues, health authority queries, and regulatory obligations.
  • Author, coordinate, review, and execute submissions and responses to regulatory authorities related to Investigational New Drugs, amendments, supplements, aggregate reports, and New Drug Applications within company timelines and applicable regulations and guidelines.
  • Independently manage preparation of Investigational New Drug applications, Clinical Trial Applications, amendments, supplements, and aggregate reports within company timelines and applicable regulations and guidelines.
  • Confirm that submission documents are accurate, compliant, and high quality to support smooth and expeditious regulatory authority approvals.
  • Serve as the sponsor point of contact for the health authority.
  • Represent Global Regulatory Affairs in project team meetings and provide regulatory guidance and perspective to cross-functional teams, in conjunction with the Global Regulatory Lead, to determine appropriate actions to meet timelines or resolve issues.
  • Manage and direct internal support staff and external consultants for assigned projects.
  • Interact with internal and external functional business units to gather data and develop documentation required for on-time submissions.
  • Work with the Global Regulatory Affairs department to execute departmental initiatives that improve overall efficiency, quality, or output.
  • Assess and develop innovative ideas to help the Global Regulatory Affairs department address current and future challenges.
Desired Qualifications
  • Regulatory Affairs Certification.
  • Experience with Food and Drug Administration or other health authority interactions.

About the company

Otsuka Pharmaceutical develops and markets medicines and health products worldwide, including prescription drugs and nutraceutical beverages. Its product lineup ranges from pharmaceutical treatments such as Abilify (an antipsychotic) to consumer health drinks like Pocari Sweat, which helps replenish electrolytes. Abilify works as a psychiatric medication used to treat conditions such as schizophrenia and bipolar disorder, while Pocari Sweat is an ion-replacement beverage designed to restore minerals and fluids after activity or heat. The company differentiates itself through a long history dating back to its founding in 1921, a broad, globally scaled portfolio spanning drugs and health beverages, and a focus on health improvements across populations. Its stated goal is to create new products for better health worldwide.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1921

Get referred to Otsuka Pharmaceutical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • VOYXACT's August 2026 two-year data supports a supplemental FDA approval filing.
  • Transcend acquisition closed June 15, 2026, adding a differentiated neuropsychiatry pipeline.
  • Paradise renal denervation gained Japan insurance coverage March 1, 2026, accelerating sales.

What critics are saying

  • Abilify patents keep expiring through 2027, pressuring a legacy revenue engine.
  • Otsuka v Sun Pharma in Australia threatens ABILIFY MAINTENA patent-extension protection.
  • Transcend's PTSD asset, TSND-201, reaches Phase 3 completion only in late 2027.

What makes Otsuka Pharmaceutical unique

  • Otsuka pairs pharmaceuticals, devices, and diagnostics across renal, psychiatric, and cardiovascular care.
  • SIMTRIYO, approved July 23, 2026, is the first approved NDSRI for ADHD.
  • VOYXACT delivered 24-month eGFR stabilization, strengthening Otsuka's IgA nephropathy leadership.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Tuition Reimbursement

Student Loan Assistance

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Otsuka US
Sep 20th, 2026
Otsuka Completes Acquisition of Transcend Therapeutics to Advance Next-Generation Neuropsychiatric Treatments | Otsuka US

Otsuka America, Inc., a subsidiary of Otsuka Pharmaceutical Co., Ltd. has completed the acquisition of Transcend Therapeutics, Inc., a clinical-stage biotechnology company developing a rapid-acting treatment for post-traumatic stress disorder (PTSD). This is the latest in a series of investments Otsuka has made to advance next-generation treatments for serious neuropsychiatric conditions.

Associated Press
Jul 25th, 2026
FDA approves Otsuka's Simtriyo, first-in-class ADHD treatment for adults and children 6+

Otsuka Pharmaceutical has received FDA approval for SIMTRIYO (centanafadine), the first norepinephrine, dopamine, serotonin reuptake inhibitor for treating ADHD in adults and children aged six years and older weighing at least 20kg. The once-daily extended-release capsule will be available later this year following DEA scheduling. The approval is based on four Phase 3 clinical trials showing statistically significant improvements in ADHD symptoms compared to placebo, with benefits observed as early as week one. Common side effects include decreased appetite, nausea, rash, and headache. ADHD affects approximately 7 million children and 15.5 million adults in the US. The drug carries boxed warnings for suicidal ideation in pediatric patients and potential for abuse and addiction.

SonoThera
Jun 10th, 2026
SonoThera Closes Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Ultrasound-Mediated Nonviral Genetic Medicines - SonoThera

SAN FRANCISCO–SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines.

Dealroom.co
Mar 27th, 2026
Transcend Therapeutics company information, funding & investors

Transcend Therapeutics, developing the next generation of psychoactive compounds for neuropsychiatry focused on patient access. Here you'll find information about their funding, investors and team.

Fierce Biotech
Mar 27th, 2026
Otsuka buys Transcend Therapeutics for $700M upfront in psychiatric drugs deal

Otsuka Pharmaceutical has acquired Transcend Therapeutics for $700 million upfront through its subsidiary Otsuka America, with potential milestone payments of up to $525 million. The deal gives Otsuka access to Transcend's MDMA analogue for psychiatric conditions currently in development.